Conditions: Stomach Neoplasms
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 76
Healthy volunteers: no

Brief summary:
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: capecitabine intervention 2: oxaliplatin intervention 3: sunitinib malate intervention 4: capecitabine intervention 5: cisplatin intervention 6: sunitinib malate
Intervention descriptions: intervention 1: Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period. intervention 2: Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. intervention 3: sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period. intervention 4: Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period. intervention 5: Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. intervention 6: sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.

Protocol document: